Table 2. Patients' outcome according to leukemic stem cell detection and TKI therapy.
| A) LSCs+ / TKI-ON | ||||
|---|---|---|---|---|
| Patient | Therapy | Sokal Score | Duration of TKI therapy (months) | Outcome |
| P13 | Imatinib | High | 108 | Persistent deep MR (>MR4) |
| P18 | Imatinib | Intermediate | 144 | Persistent deep MR (>MR4) |
| B) LSCs+ / TKI-OFF | ||||
|---|---|---|---|---|
| Patient | Therapy | Sokal Score | Duration of TKI therapy (months) | Outcome |
| P2 | Imatinib | Low | 89 | Persistent deep MR (>MR4), fluctuation of the blood BCR-ABL1/ABL1 ratio |
| P8 | Imatinib | Intermediate | 72 | MMR loss, Imatinib retreatment, MR4.5 on Imatinib |
| C) LSCs- / TKI-ON | ||||
|---|---|---|---|---|
| Patient | Therapy | Sokal Score | Duration of TKI therapy (months) | Outcome |
| P1 | Imatinib 800 | High (AP) | 84 | Persistent deep MR (>MR4) |
| P5 | Imatinib | N/A | 144 | Persistent deep MR (>MR4) |
| P10 | Imatinib | High (AP) | 150 | Persistent deep MR (>MR4) |
| P12 | Imatinib | Low | 132 | Persistent deep MR (>MR4) |
| P14 | Imatinib | Intermediate | 144 | Persistent deep MR (>MR4) |
| P17 | Imatinib | Intermediate | 45 | Persistent deep MR (>MR4) |
| D) LSCs- / TKI-OFF | ||||
|---|---|---|---|---|
| Patient | Therapy | Sokal Score | Duration of TKI therapy (months) | Outcome |
| P3 | Imatinib | Low | 92 | Persistent deep MR (>MR4), fluctuation of the blood BCR-ABL1/ABL1 ratio |
| P4 | Dasatinib | High | 19 | Persistent deep MR (>MR4) until death from Alzheimer's disease |
| P6 | Imatinib/ARA-C | Low | 96 | Persistent deep MR (>MR4.5), fluctuation of the blood BCR-ABL1/ABL1 ratio |
| P7 | Imatinib | Low | 69 | Persistent deep MR (>MR4.5), fluctuation of the blood BCR-ABL1/ABL1 ratio |
| P9 | Imatinib | Low | 71 | MMR loss, Imatinib retreatment, new Imatinib discontinuation, >MR4, fluctuation of the blood BCR-ABL1/ABL1 ratio |
| P11 | Imatinib | Low | 81 | Persistent deep MR (>MR4.5) |
| P15 | Imatinib | High | 84 | Persistent deep MR (>MR4) |
| P16 | Imatinib | High | 28 | MMR loss, Imatinib retreatment, MR4.5 on Imatinib |
| P19 | Imatinib | Intermediate | 65 | MMR loss, Imatinib retreatment, MR4.5 on Imatinib |
| P20 | Imatinib | Intermediate | 47 | Persistent deep MR (>MR4), fluctuation of the blood BCR-ABL1/ABL1 ratio |
| P21 | Imatinib | Intermediate | 133 | MMR loss, Imatinib retreatment, MR4.5 on Imatinib |
TKI: tyrosine kinase inhibitor, LSCs: leukemic stem cells (expressing BCR-ABL1 mRNA transcript), MR: molecular response, MMR: major molecular response, AP: accelerated phase, N/A: not available, ARA-C: cytarabine.